Targeting the source.
Transforming the outcome.

We develop miRNA-based therapies that address the root causes of neurological diseases. This goes far beyond the limitations of current treatment options, which only manage individual symptoms.

Read more

A future where patients with neurological diseases are effectively treated

We are committed to unlocking the full potential of miRNA therapy as a new frontier in the treatment of neurological diseases. With diligence and creativity, we advance promising therapies that harness the power of miRNA biology to effectively treat diseases such as Epilepsy and Parkinson’s.

Building on this commitment, we engage with patients, caregivers and the medical community to ensure we’re working towards outcomes that are truly life changing.

Our Science
Our miRNA-targeting approach restores balance by guiding neural networks back to healthy function.
Read more
For Patients
Conventional medicine for neurological disease has limitations. By correcting the root causes of disease, our miRNA therapies remedy its diverse impacts for improved patient outcomes.
Read more

We share our latest development updates, scientific publications and industry perspectives

8.7.2025
Neumirna Appoints Ina Brünig-Traebert as Chief Development Officer
With a proven track record in RNA therapies, Ina will guide Neumirna’s transition into clinical-stage development.
Read more
12.6.2025
Neumirna Receives 2024 CURE Epilepsy Catalyst Award
$250,000 in funding to support biomarker research and development of RNA therapy for drug-resistant epilepsy
Read more
11.6.2025
Neumirna Receives 2025 Epilepsy Foundation Shark Tank Investment
$200,000 award supports Neumirna’s RNA-based approach to innovation in epilepsy treatment
Read more
See all news

Investors

Work with us

Interested in joining Neumirna? Explore current career opportunities or contact us to learn how you can contribute to our mission.

Learn more